The present invention relates to compounds of formula I wherein R.sup.1 and R.sup.2 are as defined in the specification and to pharmaceutically acceptable salts thereof for the treatment of diseases, which are mediated by monoamine oxidase B inhibitors, for example Alzheimer's disease and senile dementia.